Photo: streetinsider.com
"Sight Sciences Elects Financial Compliance, Focuses on Meibomian Gland Care"
Sight Sciences, Inc. has established jurisdiction-wide pricing for CPT® code 0563T, enhancing Meibomian gland care under Medicare (United States) fee-for-service models.
- On October 17, 2025, Sight Sciences, Inc. announced jurisdiction-wide pricing for CPT® code 0563T, which pertains to procedures involving the eyelid and Meibomian gland.
- This strategic move aims to improve patient access to Meibomian gland treatments, aligning with Medicare (United States) fee-for-service structures to boost healthcare affordability.
- The announcement comes from Menlo Park, California, as Sight Sciences, Inc. continues to innovate within the ophthalmic industry, particularly regarding eyelid health and its related trademark procedures.
Why It Matters
This development is significant as it may enhance treatment accessibility for patients suffering from Meibomian gland dysfunction, reflecting broader trends in healthcare aimed at improving service delivery and cost management under Medicare (United States).